Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (621-630 of 692) with videos related to

Pageof 70
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 17, 2019
Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III studyW J A Witlox, B L T Ramaekers, M A Joore, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
Clinical Pharmacokinetics|March 12, 2026
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost EffectivenessYan Wang, Laura H Bukkems, Rob Ter Heine, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Eclinicalmedicine|May 1, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerG D Marijn Veerman, Rene J Boosman, Merel Jebbink, et al.
Clinical Pharmacokinetics|January 12, 2026
Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost EffectivenessYang Wang, Laura H Bukkems, Rob Ter Heine, et al.
Clinical Pharmacokinetics|May 19, 2026
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost EffectivenessYan Wang, Laura H Bukkems, Rob Ter Heine, et al.
Lung Cancer (Amsterdam, Netherlands)|August 17, 2021
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinomaChristi M J Steendam, Robert Peric, Nico C van Walree, et al.
American Journal of Respiratory and Critical Care Medicine|July 30, 2011
DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancerRobert A A van Boerdonk, Thomas G Sutedja, Peter J F Snijders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Pageof 70

Showing results (621-630 of 692) with videos related to

Sort By:
Pageof 70
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 17, 2019
Health-related quality of life after prophylactic cranial irradiation for stage III non-small cell lung cancer patients: Results from the NVALT-11/DLCRG-02 phase III studyW J A Witlox, B L T Ramaekers, M A Joore, et al.
JTO Clinical and Research Reports|August 12, 2025
Longitudinal Circulating Tumor DNA-Guided Resistance Analysis During Second-Line Osimertinib TreatmentJ W Tijmen van der Wel, Merel Jebbink, Vincent van der Noort, et al.
Clinical Pharmacokinetics|March 12, 2026
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost EffectivenessYan Wang, Laura H Bukkems, Rob Ter Heine, et al.
Future Oncology (London, England)|February 15, 2024
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancerGregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Eclinicalmedicine|May 1, 2023
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerG D Marijn Veerman, Rene J Boosman, Merel Jebbink, et al.
Clinical Pharmacokinetics|January 12, 2026
Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost EffectivenessYang Wang, Laura H Bukkems, Rob Ter Heine, et al.
Clinical Pharmacokinetics|May 19, 2026
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost EffectivenessYan Wang, Laura H Bukkems, Rob Ter Heine, et al.
Lung Cancer (Amsterdam, Netherlands)|August 17, 2021
Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinomaChristi M J Steendam, Robert Peric, Nico C van Walree, et al.
American Journal of Respiratory and Critical Care Medicine|July 30, 2011
DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancerRobert A A van Boerdonk, Thomas G Sutedja, Peter J F Snijders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2023
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, et al.
Pageof 70